Articles tagged with Multiple Sclerosis
CEMIP is associated with the breakdown of myelin, a protective sheath around nerve cells. Elevated levels of the enzyme inhibit myelin regeneration in people with multiple sclerosis. Researchers hope targeting CEMIP may promote central nervous system repair and slow disease progression.
Researchers discovered that a missing piece of myelin in nerve cells slows signal transmission to the thalamus, disrupting communication loops and cognitive tasks. This finding sheds light on symptoms associated with grey matter lesions in MS.
A study published in JAMA Network Open found that older adults with chronic kidney disease or cerebrovascular disease are at double the risk for developing neuroinvasive West Nile virus infection, which can lead to paralysis and death. The study identified several risk factors, including male sex, immune suppressants, and multiple scle...
Two first-in-class antibodies, C01 and C04, have been developed to inhibit inflammation in autoimmune diseases by blocking the high-affinity IgG receptor FcγRI. The antibodies were discovered using a unique immunization method and exhibit higher affinity for FcγRI than human IgG.
Researchers at the University of Illinois Chicago have developed a novel multiple sclerosis treatment that utilizes nanoparticle-boosted myeloid-derived suppressor cell therapy. This innovative approach aims to reprogram the immune system and promote tolerance in patients with MS.
Researchers created a multidimensional molecular map of brain development after birth and its response to inflammation, finding that some developmental programmes can be reactivated during neuroinflammation. This study provides new clues for understanding how myelin is broken down in diseases like MS.
A University of Houston researcher identifies a protein that may reduce high ketone levels in diabetic patients, potentially improving health outcomes. The study also shows that the protein promotes muscle ketolysis and running capacity in mice.
A UK-wide study of 5,509 people with MS found that the condition significantly affects health-related quality of life. The research used EQ-5D-5L tool to measure changes in health status, revealing varying thresholds by MS type and relapse history.
Researchers found that people with MS have a distinct oral microbiome compared to healthy individuals, characterized by a loss of beneficial bacteria and an increase in disease-causing bacteria. The study suggests that oral microbial and metabolic changes may contribute to inflammation and disease processes in MS.
Scientists analyzed thousands of proteins in blood samples to understand when multiple sclerosis attacks the myelin sheath and nerve fibers. Researchers identified a protein called IL-3, which plays a key role in this early phase of damage.
Researchers at UCLA Health have identified a sex-chromosome linked gene that drives inflammation in the female brain, making women more susceptible to conditions like Alzheimer's disease and multiple sclerosis. Deactivating this gene and using diabetes medication metformin showed promising results in reducing symptoms in female mice.
A multidisciplinary study at Texas A&M University finds that estrogens estradiol and estriol may reduce symptoms of progressive MS by decreasing inflammation in the spinal cord. Estradiol also significantly decreases damage to the myelin sheath, a protective coating around nerve fibers, making it a promising therapeutic intervention.
Researchers identify disease-associated radial glia-like cells that contribute to persistent inflammation and neurodegeneration in progressive multiple sclerosis. These cells exhibit characteristic features of radial glia and display hallmark features of premature aging, fuelling a toxic environment that accelerates neurodegeneration.
Scientists have identified two compounds, K102 and K110, that could promote remyelination and modulate immune function in multiple sclerosis. These compounds showed promising results in mouse models and human cells, suggesting potential for treating MS and possibly other neurological diseases.
A study by UC Riverside researchers identifies a strong connection between demyelination and seizure activity in multiple sclerosis. The findings suggest targeted treatments could address the root cause of seizures without suppressing overall brain activity.
The review highlights the critical roles of phospholipids in regulating immune cell migration, differentiation, and survival, as well as their regulatory effects on inflammation. Dysregulated phospholipid metabolism is linked to various diseases, including autoimmune disorders, cardiovascular disease, and cancer.
Researchers have developed a tool that can predict how patients with multiple sclerosis will respond to natalizumab treatment, allowing for targeted treatments with fewer side effects. The tool uses high-content imaging and machine learning to analyze cell morphology and identify individuals who are unlikely to respond to the medication.
New research reveals that menopause may significantly influence how multiple sclerosis first presents in women, with distinct differences in symptom patterns and associated health conditions. The analysis found that postmenopausal women experienced more frequent cardiovascular disease and metabolic disorders.
New research links higher intake of ultra-processed foods to more frequent relapses and greater MRI-detected lesion activity in early multiple sclerosis. Researchers found that increased consumption was associated with disrupted gut barrier function, immune activation, and cellular energy production problems.
A multi-registry study found ocrelizumab superior to other treatments in reducing MS relapse rates. Ocrelizumab outperformed fingolimod, natalizumab, and alemtuzumab in controlling multiple sclerosis relapses.
The American College of Chest Physicians has achieved a critical milestone in its advocacy efforts, leading to changes in federal coverage guidelines for noninvasive ventilation devices used in the home. These revised guidelines reflect major recommendations submitted by CHEST and aim to enhance patient care.
A study of Medicare database payments found that nearly 80% of US neurologists prescribing multiple sclerosis (MS) drugs received industry payments, with higher volume prescribers more likely to be beneficiaries. Recipients were also more likely to prescribe the company's drugs, especially if payments were larger and sustained.
The International Progressive MS Alliance has launched the MS Clinical and Imaging Data Resource (CIDR), providing access to anonymized data from thousands of people with MS who participated in clinical trials. The resource aims to accelerate research on progressive MS by enabling investigators to conduct more informed studies and spee...
A new study has identified a genetic biomarker that predicts which multiple sclerosis patients will respond well to treatment with glatiramer acetate. This allows for personalized therapy decisions to be made before starting treatment, with those carrying the HLA-A*03:01 gene variant showing significant clinical benefits.
People with MS show higher healthcare use up to 15 years before symptoms appear, highlighting opportunities for earlier identification and intervention. The study analyzed health records of over 12,000 people in BC and found distinct patterns of healthcare engagement before symptom onset.
A large study found that Medicare beneficiaries with multiple sclerosis who received broader coverage of MS treatments had significantly lower risk of developing new or worsening symptoms. Researchers warn that formulary exclusions for specialty drugs could lead to worse health outcomes.
A study published in Neurology found that women with multiple sclerosis are less likely to receive disease-modifying drugs than men, even when accounting for pregnancy and postpartum periods. The study suggests that women's reluctance to use these treatments may be a factor in the disparity.
A new study by University of South Australia researchers uses genetic recall to explore links between multiple sclerosis (MS) and the Epstein-Barr virus. The study aims to identify early warning signs or biomarkers for MS, enabling early detection and intervention.
A study by the University of Eastern Finland found that physical performance is associated with better cognition in people with relapsing-remitting MS. The study measured cognitive function, disability, and physical activity using various tests, revealing a significant link between these factors.
Researchers at the University of Cambridge have made a groundbreaking discovery on how neural stem cell grafts can restore myelin in MS lesions in mice. The study provides critical evidence supporting the safety and efficacy of human induced neural stem cell transplantation as a potential new treatment for progressive multiple sclerosis.
Researchers have developed a novel treatment approach for autoimmune diseases by engineering a protein that holds closely together two signaling complexes on T cells, shutting down those T cells in a limited way. This approach shows promise for treating conditions such as Type-1 diabetes and multiple sclerosis.
Researchers discovered that children with MS show signs of accelerated biological aging, even in their teenage years, which may lead to new treatment possibilities beyond immunosuppression. The study found that youth with MS had evidence of accelerated epigenetic age, a measurement of DNA chemical modifications associated with aging.
A study of twins reveals that certain bacteria in the small intestine may trigger MS. Researchers identified two specific bacteria, Lachnoclostridium sp and Eisenbergiella tayi, which are associated with the disease. The findings suggest a new potential therapeutic target for MS treatment.
The National Multiple Sclerosis Society is offering funding opportunities for next-generation researchers and clinicians, as well as projects advancing women's health in MS. The American Brain Foundation and US Department of Defense are also providing grants for neuroinflammation research and clinical trials.
A new study published in Neurology Open Access found that an MRI scan can accurately diagnose multiple sclerosis (MS) in just 8 minutes, eliminating the need for a painful spinal tap. The study's findings support the use of a T2*-weighted MRI and a 'rule of six' to confirm a diagnosis without lumbar puncture.
The National Multiple Sclerosis Society has committed $18.1 million to support research projects aligned with its Pathways to Cures roadmap, which aims to stop MS, restore function, and end the disease. The funding includes 16 research grants and 28 training fellowships in the US and internationally.
Researchers at University of Turku discovered a new biomarker that correlates the thickness of inflammatory cell rim surrounding brain lesions with disease severity and speed. The wider the rim, the more aggressively the disease advances, allowing for earlier treatment identification and evaluating drug candidates.
The International Progressive MS Alliance has awarded €100,000 to three development project teams to plan clinical trials. The projects focus on developing new treatments for progressive MS, including exercise-induced fatigability, neural stem cell therapy, and salbutamol treatment.
A new AI model developed by Uppsala University accurately diagnoses multiple sclerosis (MS) with an overall accuracy of 90%, identifying the transition from relapsing-remitting to secondary progressive MS in almost 87% of cases. This enables earlier diagnosis, reducing the risk of patients receiving ineffective medicines.
The Consortium of Multiple Sclerosis Centers released a new 2025 Best Practices Update to help healthcare providers stay up-to-date with the latest advances in MS care. The document addresses evolving disease classification, additional disease-modifying therapies, and newer biomarkers to detect changes in disease progression.
A rodent study found hnRNP A1 regulates myelin production and maintains its integrity, suggesting an impact on neurodegenerative diseases like schizophrenia. The findings provide new insights into the disease's molecular basis and potential treatments.
University of Cincinnati researchers, in collaboration with end users, develop a user-centered, easy-to-use assistive device to help restore hand grasping motions. The team aims to combine an exoskeleton device with functional electrical stimulation (FES) technology to create a hybrid system.
A phase 3 trial demonstrated a 31% delay in confirmed disability progression in patients with non-relapsing secondary progressive multiple sclerosis. Tolebrutinib, an oral Bruton's tyrosine kinase inhibitor, showed promise as a potential treatment option for this form of the disease.
Neuro-immunologist Stephen Hauser has won the 2025 Breakthrough Prize in Life Sciences for his role in identifying the immune system's primary driver of damage to nerve cells in multiple sclerosis. His B-cell theory has led to the development of therapies that have transformed treatment, reducing relapses and improving prognosis.
A new AI tool called MindGlide can extract key information from brain images to measure damaged areas and highlight subtle changes in MS patients. The tool performed better than other AI tools and expert clinical analysis, enabling researchers to unlock valuable insights into multiple sclerosis.
Scientists have long believed that cells respond to stress in a linear chain of events, but a new study reveals a more complex 'split-integrated stress response' that can be fine-tuned depending on the type and intensity of stress. This flexibility could lead to new targets for treating cancer and neurodegenerative diseases.
Dr. Amit Bar-Or is awarded the 2025 John Dystel Prize for his contributions to neuroimmunology and precision medicine in multiple sclerosis research. His work has led to significant advancements in disease mechanisms, treatment approaches, and biomarker studies.
Scientists at the University of South Australia have developed a phospholipid complex to improve cannabidiol's effectiveness in treating epilepsy, multiple sclerosis, and other neurodegenerative diseases. The new formula increases cannabidiol's solubility by up to six times and improves its absorption in the gastrointestinal tract.
A new gamified mobile health app, More Stamina, has been shown to effectively manage MS-related fatigue by helping users track their daily activities and energy expenditure. The study found that the app facilitated conversations between MS patients and their families, improving understanding and support.
A new study published in Multiple Sclerosis and Related Disorders highlights the potential of a gamified mobile health app to help people with Multiple Sclerosis (MS) manage fatigue. The app, More Stamina, uses a gamified approach to visualize energy use and facilitate discussions with family members and healthcare providers.
Research finds that certain viral antibodies and genetic risk factors can increase MS risk, with elevated antibody levels combined with a specific gene variant associated with strong increased risk. The study also identifies potential biomarkers for early diagnosis.
A preliminary study found that a simple algorithm can rapidly increase the use of newer, more effective treatments for MS among all three groups, greatly improving health. The algorithm matches people to treatments based on clinical factors like weakness and bladder dysfunction, as well as social factors.
Researchers at the National Institutes of Health (NIH) have created a four-dimensional brain map that reveals how lesions similar to those seen in human MS form. The findings provide insight into early disease state changes and could help identify potential targets for MS treatments and brain tissue repair.
A high dietary intake of lean and oily fish may slow the progression of disability in people with MS, according to a comparative population-based study. The anti-inflammatory and neuroprotective properties of nutrients found in fish may be key to managing the disease.
In Finland, MS treatment has undergone significant changes over the past decade, with diagnoses now made within five months of symptoms onset. New, highly effective treatments have become the standard first-line treatment, improving patient outcomes and quality of life.
The CMSC Annual Meeting brings together experts to share cutting-edge research and innovative treatment approaches. Healthcare professionals can earn continuing education credits while expanding their expertise in MS care.
A new sponge-like implant helps guide a treatment that slows or stops a degenerative condition similar to multiple sclerosis. The implant attracted diseased immune cells, enabling researchers to study and target them with a nanoparticle-based treatment, which prevented mice from developing symptoms such as paralysis if administered early.
A comprehensive review published in Brain Medicine maps out the extensive influence of reproductive hormones on neurological health and disease. The study examines how sex hormones affect a broad spectrum of neurological conditions, including vascular disorders, movement disorders, epilepsy, multiple sclerosis, and Alzheimer's disease.
Researchers at UCF aim to create mobile robotic assistants that offer easier control and a better robot-human interface. The project, supported by a $600,000 grant, will focus on testing and user feedback, with initial trials conducted with students and adults with upper body paralysis.
A rare case report highlights the association between systemic mastocytosis and severe osteoporosis in a young adult patient, emphasizing the importance of early diagnosis and consideration of SM as an underlying cause. The study aims to raise awareness about this underrecognized condition and its potential impact on bone health.